Nasofan (Fluticasone Propionate)

Fluticasone propionate is a synthetic glucocorticoid that binds to glucocorticoid receptors in nasal mucosal cells. The drug‑receptor complex then modulates gene expression, suppressing the production of pro‑inflammatory cytokines and limiting the migration of inflammatory cells, which reduces swelling and mucus formation in the nose.

The exact dosing regimen for Nasofan is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and response to therapy. Typically, one or two sprays per nostril once or twice daily are used, but the prescriber will provide the specific instructions for each individual.

Safety data for fluticasone propionate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting Nasofan.

To order Nasofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nasofan contains fluticasone propionate, which is among the most potent topical glucocorticoids for nasal use. Compared with older agents such as beclomethasone or budesonide, fluticasone offers a higher receptor affinity and a lower systemic absorption profile, often resulting in effective symptom control with a reduced risk of systemic side effects.

Nasofan should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiry date printed on the packaging.

Nasofan is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The same procedure is repeated for the other nostril if required.

Serious risks, though uncommon, include adrenal suppression with prolonged high‑dose use, development of glaucoma or cataracts, severe nasal septum perforation, and opportunistic fungal infections of the nasal cavity. Patients should report persistent nosebleeds, visual changes, severe facial pain, or signs of infection to a healthcare professional promptly.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, bacterial, or viral infections of the nasal passages, and in those for whom systemic corticosteroid therapy is contraindicated.